1887

Abstract

Vesicular stomatitis (VS) is a notifiable disease of livestock affecting cattle, horses, pigs and humans. Vesicular stomatitis virus (VSV) serotypes Indiana and New Jersey are endemic to Central America; however, they also cause sporadic and scattered outbreaks in various countries in South and North America, including the USA. In order to develop an effective experimental challenge model for VSV, we compared the pathogenicity of three VSV serotype Indiana isolates in 36 4–5 week-old pigs. Two bovine isolates of Central American origin and one equine isolate from the USA were used for the experimental infections. Each pig was inoculated with a single isolate by both the intradermal and intranasal routes. Clinical signs of VSV infection were recorded daily for 10 days post-inoculation (days p.i.). Nasal and tonsillar swab samples and blood were collected to monitor immune responses, virus replication and shedding. Post-challenge, characteristic signs of VS were observed, including vesicles on the nasal planum and coronary bands, lameness, loss of hoof walls and pyrexia. Pigs inoculated with the Central American isolates showed consistently more severe clinical signs in comparison to the pigs infected with the USA isolate. Genomic RNA was isolated from the original challenge virus stocks, sequenced and compared to VSV genomes available in GenBank. Comparative genome analysis demonstrated significant differences between the VSV isolate from the USA and the two Central American isolates. Our results indicate that the Central American isolates of VSV serotype Indiana used in this study are more virulent in swine than the USA VSV serotype Indiana isolate and represent good candidate challenge strains for future VSV studies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001329
2019-11-01
2019-11-15
Loading full text...

Full text loading...

References

  1. Rodrı́guez LL. Emergence and re-emergence of vesicular stomatitis in the United States. Virus Res 2002;85:211–219 [CrossRef]
    [Google Scholar]
  2. Rodriguez LL, Bunch TA, Fraire M, Llewellyn ZN. Re-Emergence of vesicular stomatitis in the Western United States is associated with distinct viral genetic lineages. Virology 2000;271:171–181 [CrossRef]
    [Google Scholar]
  3. Tesh RB, Peralta PH, Johnson KM. Ecologic studies of vesicular stomatitis virus. I. prevalence of infection among animals and humans living in an area of endemic VSV activity. Am J Epidemiol 1969;90:255–261 [CrossRef]
    [Google Scholar]
  4. Johnson KM, Peralta PH, Vogel JE. Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 1966;15:244–246 [CrossRef]
    [Google Scholar]
  5. Iverson LE, Rose JK. Sequential synthesis of 5'-proximal vesicular stomatitis virus mRNA sequences. J Virol 1982;44:356–365
    [Google Scholar]
  6. Spiropoulou CF, Nichol ST. A small highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatitis virus. J Virol 1993;67:3103–3110
    [Google Scholar]
  7. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998;72:4704–4711
    [Google Scholar]
  8. Roberts A, Buonocore L, Price R, Forman J, Rose JK. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999;73:3723–3732
    [Google Scholar]
  9. Whelan SP, Ball LA, Barr JN, Wertz GT. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 1995;92:8388–8392 [CrossRef]
    [Google Scholar]
  10. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 1995;92:4477–4481 [CrossRef]
    [Google Scholar]
  11. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016;374:1647–1660 [CrossRef]
    [Google Scholar]
  12. ElSherif MS, Brown C, MacKinnon-Cameron D, Li L, Racine T et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. Can Med Assoc J 2017;189:E819–E827 [CrossRef]
    [Google Scholar]
  13. Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 2015;15:1156–1166 [CrossRef]
    [Google Scholar]
  14. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet 2017;389:505–518 [CrossRef]
    [Google Scholar]
  15. Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 2017;377:1438–1447 [CrossRef]
    [Google Scholar]
  16. Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L et al. Six-Month safety data of recombinant vesicular stomatitis Virus–Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis 2017;215:1789–1798 [CrossRef]
    [Google Scholar]
  17. Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 2017;376:330–341 [CrossRef]
    [Google Scholar]
  18. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539–549 [CrossRef]
    [Google Scholar]
  19. Betancourt D, de Queiroz NMGP, Xia T, Ahn J, Barber GN. Cutting edge: innate immune augmenting vesicular stomatitis virus expressing Zika virus proteins confers protective immunity. J Immunol 2017;198:3023–3028 [CrossRef]
    [Google Scholar]
  20. DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. Single-Dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine 2014;32:2637–2644 [CrossRef]
    [Google Scholar]
  21. Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis Virus–based vaccines against Lassa and Ebola viruses. Emerg Infect Dis 2015;21:305–307 [CrossRef]
    [Google Scholar]
  22. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis Virus–Based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011;204:S1075–S1081 [CrossRef]
    [Google Scholar]
  23. de Wit E, Marzi A, Bushmaker T, Brining D, Scott D et al. Safety of recombinant VSV–Ebola virus vaccine vector in pigs. Emerg Infect Dis 2015;21:702–704 [CrossRef]
    [Google Scholar]
  24. Rodriguez LL, Pauszek SJ, Bunch TA, Schumann KR. Full-Length genome analysis of natural isolates of vesicular stomatitis virus (Indiana 1 serotype) from North, central and South America. J Gen Virol 2002;83:2475–2483 [CrossRef]
    [Google Scholar]
  25. Shahan MS, Frank AH, Mott LO. Studies of vesicular stomatitis with special reference to a virus of swine origin. J Am Vet Med Assoc 1946;108:5–19
    [Google Scholar]
  26. Stallknecht DE, Greer JB, Murphy MD, Mead DG, Howerth EW. Effect of strain and serotype of vesicular stomatitis virus on viral shedding, vesicular lesion development, and contact transmission in pigs. Am J Vet Res 2004;65:1233–1239 [CrossRef]
    [Google Scholar]
  27. Martinez I, Rodriguez LL, Jimenez C, Pauszek SJ, Wertz GW. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 2003;77:8039–8047 [CrossRef]
    [Google Scholar]
  28. Martinez I, Barrera J, Rodriguez L, Wertz G. Recombinant vesicular stomatitis (Indiana) virus expressing new Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. Vaccine 2004;22:4035–4043 [CrossRef]
    [Google Scholar]
  29. Redelman D, Nichol S, Klieforth R, Van Der Maaten M, Whetstone C. Experimental vesicular stomatitis virus infection of swine: extent of infection and immunological response. Vet Immunol Immunopathol 1989;20:345–361 [CrossRef]
    [Google Scholar]
  30. Velazquez-Salinas L, Pauszek SJ, Stenfeldt C, O'Hearn ES, Pacheco JM et al. Increased virulence of an epidemic strain of vesicular stomatitis virus is associated with interference of the innate response in pigs. Front Microbiol 1891;2018:9
    [Google Scholar]
  31. Hole K, Velazquez-Salinas L, Velazques-Salinas L, Clavijo A. Improvement and optimization of a multiplex real-time reverse transcription polymerase chain reaction assay for the detection and typing of vesicular stomatitis virus. J Vet Diagn Invest 2010;22:428–433 [CrossRef]
    [Google Scholar]
  32. Hamilton MA, Russo RC, Thurston RV. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 1977;11:714–719 [CrossRef]
    [Google Scholar]
  33. Howerth EW, Stallknecht DE, Dorminy M, Pisell T, Clarke GR. Experimental vesicular stomatitis in swine: effects of route of inoculation and steroid treatment. J Vet Diagn Invest 1997;9:136–142 [CrossRef]
    [Google Scholar]
  34. Stallknecht DE, Perzak DE, Bauer LD, Murphy MD, Howerth EW. Contact transmission of vesicular stomatitis virus new Jersey in pigs. Am J Vet Res 2001;62:516–520 [CrossRef]
    [Google Scholar]
  35. Clarke GR, Stallknecht DE, Howerth EW. Experimental infection of swine with a sandfly (Lutzomyia shannoni) isolate of vesicular stomatitis virus, New Jersey serotype. J Vet Diagn Invest 1996;8:105–108 [CrossRef]
    [Google Scholar]
  36. Smith PF, Howerth EW, Carter D, Gray EW, Noblet R et al. Host predilection and transmissibility of vesicular stomatitis new Jersey virus strains in domestic cattle (Bos taurus) and swine (Sus scrofa). BMC Vet Res 2012;8:183 [CrossRef]
    [Google Scholar]
  37. Letchworth GJ, Rodriguez LL, Del cbarrera J. Vesicular stomatitis. Vet J 1999;157:239–260 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001329
Loading
/content/journal/jgv/10.1099/jgv.0.001329
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error